| Drug Type Peptide Conjugate Radionuclide, Diagnostic radiopharmaceuticals | 
| Synonyms- | 
| Target | 
| Action modulators | 
| Mechanism PSMA modulators(Prostate-specific membrane antigen modulators) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePreclinical | 
| First Approval Date- | 
| Regulation- | 

| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Prostatic Cancer | Preclinical | United States  | 26 May 2023 | 





